Wearable Injectors and Connected Devices Conference 2020

SMi Group 7 - 8 October 2020, London, United Kingdom.
The global wearable devices market size is expected to reach a value of $62.82 billion USD by 2025 with time dependent delivery, improved patient experience and adherence and large volume administration with minimal injection pain and being key factors driving the market.

With that in mind, SMi is proud to present Europe's only Wearable Injectors Conference, taking place on the 7th-8th of October 2020, in London.

SMi's 2nd annual Wearable Injectors and Connected Devices conference will explore the latest digital applications for on-body devices through industry case studies and perspectives, advances in device design for large volume delivery, drug/device compatibility for wearable injectors and real world examples from industry thought leaders on a patient-centric approach. Furthermore, the key regulatory considerations and guidance of the field will be presented by regulatory, notified body and industry experts for a comprehensive outlook of this exciting and ever-growing field.

This two-day agenda offers you peer-to-peer networking with Global Device Development Managers, Senior Connectivity Engineers, Leaders in Device Data Generation, Human Factors Directors and many more.

Benefits of Attending

  • EXPLORE the growing potential of connectivity and digital health to improve patient experience and treatment
  • UNDERSTAND the key regulatory considerations in industry with representation from regulatory and notified bodies
  • ASSESS advances in device design and development for large volume delivery via on-body injectors
  • GAIN insights into drug/device compatibility and packaging for wearable injectors

Early-Bird Rates

  • Book by June 30th to save £300
  • Book by August 31st to save £200

For further information and to register, please visit:
http://www.wearable-injectors.co.uk/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

Johnson & Johnson statement on COVID-19 vaccin…

The safety and well-being of the people who use our products is our number one priority. We are aware of an extremely rare disorder involving people with blood clots in c...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

GSK and Vir Biotechnology announce EMA review of d…

GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational...

Phase III prevention trial showed subcutaneous adm…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail ...

Amgen successfully completes acquisition of Five P…

Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Pr...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Valneva switches focus to bilateral discussions to…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 vaccine, to the 2...

Patients who are obese or overweight are at risk f…

COVID-19 patients who are overweight or obese are more likely to develop a more severe infection than patients of healthy weight, and they require oxygen and invasive mec...

Massive fragment screen points way to new SARS-CoV…

New research published in Science Advances provides a template for how to develop directly-acting antivirals with novel modes of action, that would combat COVID-19 by sup...